恩替卡韦联合干扰素治疗乙型肝炎患者的临床疗效观察

Observation on clinical effectof Entecavir combined interferon treatment for HBV patients

目的探讨恩替卡韦联合干扰素治疗HBV的临床疗效。方法比较分析60例HBV患者在联合应用恩替卡韦和干扰素治疗24周后,在HBe Ag、HBVDNA和ALT等方面的临床疗效。结果HBVDNA转阴率86%,HBe Ag转阴率43%,ALT复常率90%(P<0.05)。结论恩替卡韦联合干扰素在治疗乙型肝炎方面远期效果好,疗效肯定。

Objective To explore the clinical effects of Entecavir combined interferon treatment for HBV virus. Methods Compared and analyzed clinical effects of Entecavir combined interferon on 60 CHB patients in HBeAg-positive, HBVDNA and ALT after 24 weeks. Results HBVDNA overcast rate 86% , HBeAg overcast rate 43% ,ALT liver function recovery rate was 90%. Conclusions The forward effect of entecavir combined interferon is good, has affirmative curative effect.